Tag: cardiomyopathy

Call for Papers

You are invited to submit an article to Cardiovascular Innovations and Applications (CVIA).

Cardiovascular Innovations and Applications (CVIA) seeks to publish focused articles and original clinical research that explore novel developments in cardiovascular disease, effective control and rehabilitation in cardiovascular disease, and promote cardiovascular innovations and applications for the betterment of public health globally. The journal publishes basic research that has clinical applicability to promote timely communication of the latest insights relating to coronary artery disease, heart failure, hypertension, cardiac arrhythmia, prevention of cardiovascular disease with a heavy emphasis on risk factor modification.

CVIA was launched in 2015 as an open access journal, offering high visibility and discoverability through its open access publishing approach. As part of its mandate to help bring interesting work and knowledge from around the world to a wider audience, CVIA will actively support authors through open access publishing and through waiving author fees.  

The journal welcomes the following article types:

  • Editorials
  • Original Research
  • Review Articles
  • Commentaries
  • Case Reports
  • Case Studies
  • Methodology papers related to clinical trials
  • Letters to the Editor

For more information on our journal please see the CVIA website https://cvia-journal.org/; recently published content is available on ScienceOpen  https://www.scienceopen.com/search#collection/32b77252-732d-468f-a6f9-9637d4762967 .

Submissions to Cardiovascular Innovations and Applications (CVIA) can be made using ScholarOne, the online submission and peer review system. Registration and access is available at https://mc04.manuscriptcentral.com/cvia-journal. There are no author submission or article processing fees.

CVIA is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ and Index Copernicus Databases.

Follow CVIA on Twitter @CVIA_Journal; or Facebook https://www.facebook.com/cvia.journal/.

Articles of interest include:

Psychosocial Risk Factors and Cardiovascular Disease: Epidemiology, Screening, and Treatment Considerations

Novel SPECT Technologies and Approaches in Cardiac Imaging

Global Burden of Cardiovascular Disease

Clinical Characteristics and Durations of Hospitalized Patients with COVID-19 in Beijing: A Retrospective Cohort Study

Rationale and Design of the Randomized Controlled Trial of Intensive Versus Usual ECG Screening for Atrial Fibrillation in Elderly Chinese by an Automated ECG System in Community Health Centers in Shanghai (AF-CATCH)

The Effect of Home-Based Cardiac Rehabilitation on Functional Capacity, Behavior, and Risk Factors in Patients with Acute Coronary Syndrome in China

Current Management Strategies in Patients with Heart Failure and Atrial Fibrillation: A Review of the Literature

Telemedicine: Its Importance in Cardiology Practice. Experience in Chile

Management of Hypertension: JNC 8 and Beyond

The Relationship Between Mean Platelet Volume and In-Hospital Mortality in Geriatric Patients with ST Segment Elevation Myocardial Infarction Who Underwent Primary Percutaneous Coronary Intervention

Loading

AHA @ GW-ICC AHA-BCVS Joint Forum – Great Wall International Congress of Cardiology (GW-ICC) 2017 – Fishing for the Cure – Molecular Insights into Amyloid Cardiomyopathy

AHA @ GW-ICC AHA-BCVS Joint Forum – Great Wall International Congress of Cardiology (GW-ICC) 2017 – Fishing for the Cure – Molecular Insights into Amyloid Cardiomyopathy

It has become a tradition for world renowned cardiology associations to send delegations to GW-ICC congresses.

Professor Jeroen J. Bax, President, European Society of Cardiology (ESC), Professor John Warner, President, American Heart Association (AHA), and Professor Mary N. Walsh, President, American College of Cardiology (ACC), led delegations attending the 28th GW-ICC, to present latest international guidance, cutting-edge diagnosis and information on treatment with emerging technologies.

Cooperation with these international societies is not limited to their attendance at GW-ICC; GW-ICC also holds reciprocal academic sessions at the annual meetings of these eminent societies, for example GW-ICC @ ACC, GW-ICC @ AHA, and GW @ ESC, to introduce important Chinese academic research.

At the 28th GW-ICC in 2017, the AHA @ GW-ICC Joint Forum, which was held over three sessions, focused on population health, guidelines and real-world evidence; cardiovascular disease prevention: hypertension, smoking cessation and blood lipid management and systems of STEMI care.

A video of one of these 2017 sessions is now available to view on the GW-ICC YouTube channel:

Fishing for the Cure – Molecular Insights into Amyloid Cardiomyopathy

Presenter: Ronglih Liao PhD, FAHA, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA.

Professor Liao discusses how:

  • Amyloidogenic protein triggered proteotoxicity is sufficient to drive mortality in zebrafish.
  • Experimentally, signaling cascades triggered by amyloidogenic proteins can be targeted for therapeutic intervention.
  • 18F Florbetapir PET imaging may be used for early diagnosis of AL amyloid cardiomyopathy.

Further information on the 29th GW-ICC, to be held October 11th -14th, 2018, in Beijing, China, is available on the congress website:

http://www.gw-icc2017.org/en/1/index.jsp

Cardiovascular Innovations and Applications (CVIA) is the official journal of the Great Wall International Cardiology Conference (GW-ICC). CVIA supports GW-ICC in its aims of leading the development of cardiovascular medicine in China, by introducing and promoting new concepts and technologies and strengthening and promoting cooperation amongst Chinese and international cardiology experts. CVIA is available on the IngentaConnect platform http://www.ingentaconnect.com/content/cscript/cvia and at https://dhn.zgc.mybluehostin.me/cvia/. Submissions may be made using Scholar One manuscripts at https:/mc04.manuscriptcentral.com/cvia-journal. There are no author submission or article processing fees.

Twitter: @CVIA_Journal

Facebook: https://www.facebook.com/cvia.journal/

Conference website: http://www.gw-icc2017.org/en/1/index.jsp

Loading

Cardiac Sarcoidosis

Cardiac Sarcoidosis: Sorting Fact from Fiction in This Rare Cardiomyopathy

Authors: Rajapreyar, Indranee; Langlois, Elizabeth

Sarcoidosis is a rare condition of granulomatous infiltration of many tissues of the body, including the heart. Cardiac sarcoidosis has been challenging to study, as it is often asymptomatic, although the initial presentation can be sudden cardiac death. The incidence and prevalence rates have been difficult to establish and no expert agreed upon guidelines for diagnosis and management of cardiac sarcoidosis exist, and clinical manifestations are varied. The pathophysiology of granuloma formation in the myocardium as well as other tissues is governed by immune response to some environmental antigen. Genetics is also thought to play a role, although gene alterations have not been extensively studied, and no specific set of genetic mutations has been identified to aid in identification of individuals at risk of developing disease. Epigenetic factors likely play a significant role in modulation of gene expression with respect to immune response. There is no standardized screening tool for the identification of cardiac sarcoidosis. The presence of systemic sarcoidosis and new-onset third-degree heart block or ventricular arrhythmias warrants further investigation for cardiac sarcoidosis. MRI and PET are useful in helping to identify cardiac sarcoidosis but are not stand-alone tests. Endomyocardial biopsy is the gold standard but has a low yield owing to the patchy nature of granuloma formation in the myocardium. Therapy should be instituted early and involves immunosuppressive therapy with predominant use of corticosteroids. Arrhythmias, either ventricular or high-grade heart blocks, are managed with device therapy. Clinical presentation may warrant use of antiarrhythmic agents and/or catheter ablation. Survival and disease prognosis are dependent on early diagnosis and treatment. This review details the current understanding of cardiac sarcoidosis and highlights diagnostic strategies and treatment with the aim of guiding the clinician to early identification of patients and implementation of appropriate management in this rare disease entity.

Loading